GSK1795091

GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. Not only, GSK1795091 inhibits tumor growth and increases the survival in mice model, but results in long term survival in influenza challenge model in mice[1][2][3].

Product Specifications

CAS Number

[1233589-81-5]

Product Name Alternative

CRX-601

UNSPSC

12352005

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gsk1795091.html

Purity

94.48

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(C[C@H](OCCCCCCCCCC)CCCCCCCCCCC)O[C@@H]([C@@H]([C@H]1CO)O[P](O)(O)=O)[C@H]([C@@H](O1)OC[C@@H](C(O)=O)NC(C[C@H](OCCCCCCCCCC)CCCCCCCCCCC)=O)NC(C[C@H](OCCCCCCCCCC)CCCCCCCCCCC)=O

Molecular Formula

C81H157N2O16P

Molecular Weight

1446.09

References & Citations

[1]Hug BA, et al. Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study. Clin Ther. 2020;42 (8) :1519-1534.e33. |[2]Maroof A, et.al. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection. PLoS Pathog. 2014 Jan;10 (1) :e1003875. |[3]Cebada J, et al. OX40 agonists for cancer treatment: a patent review. Expert Opin Ther Pat. 2021 Jan;31 (1) :81-90.